Merja Soilu-Hänninen
MD, PhD
Turku University Hospital, Division of Clinical Neurosciences mersoi@utu.fi |
Clinical neurology; neuroimmunology; multiple sclerosis risk factors, prognostic factors and treatment
MD, University of Turku 1988
PhD, University of Turku, Department of Virology, Immunobiology of central nervous system virus infections 1996
Postdoctoral Fellow, Development and Neurobiology Group, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia 1997-1999
Specialist Degree in Neurology 2001
Adjuct Professor of Clinical Neurology 2008
Inverstigator in several clinical MS trials
Chair of the Finnish MS registry 2016-
General Neurology Section Head, Turku University Hospital, Division of Clinical Neurosciences 2017-
Multiple sclerosis risk factors, prognostic factors and epidemiology.
Imaging of brain atrophy in multiple sclerosis.
Course of medical pedagogics 2011-2012
Supervisor of several PhD student
- Miksi MS-tauti yleistyy? (2022)
- DuodecimDosis
- MS-taudin ja liikehäiriöiden laaturekisterit (2022)
- Erikoislääkäri
- Neurosarkoidoosin uudistunut diagnostiikka ja tehostunut hoito (2021)
- DuodecimJournal of Neuroimmune Pharmacology
- Alemtuzumab is a budget-saving alternative to fingolimod and natalizumab in the treatment of highly active relapsing-remitting multiple sclerosis (2020)
- Changes in multiple sclerosis epidemiology in Finland over five decades (2020)
- Acta Neurologica ScandinavicaFrontiers in Neurology
- Lipid Profile Alterations during Fingolimod Treatment in Multiple Sclerosis Patients (2020)
- Medication adherence/persistence among patients with active multiple sclerosis in Finland (2020)
- Acta Neurologica ScandinavicaBrain and Behavior
- Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis (2020)
- Trends and characteristics of infection-related hospital admissions in multiple sclerosis patients in Southwest Finland in 2009–2018 (2020)
- Multiple Sclerosis and Related Disorders
- Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients2020
